Intravascular Stents Market Size

Market Outlook:

Intravascular Stents Market exceeded USD 13.4 Billion in 2023 and is expected to exceed USD 27.01 Billion by end of the year 2032, observing around 8.1% CAGR between 2024 and 2032.

• Base Year Value (2023): USD 13.4 Billion
• CAGR (2024-2032): 8.1%
• Forecast Year Value (2032): USD 27.01 Billion
• Historical Data Period: 2019-2023
• Largest Region: North America
• Forecast Period: 2024-2032

Market Dynamics:

Growth Drivers & Opportunity:

Technological advancements in stent design and materials have significantly improved the outcomes of stent procedures by reducing the risk of restenosis and enhancing patient comfort. This innovation has fueled the demand for intravascular stents and is expected to drive market growth in the coming years.

Increase in prevalence of cardiovascular diseases, such as coronary artery disease, has led to a higher demand for treatment options like intravascular stents. The rising geriatric population and unhealthy lifestyle habits are contributing to the increasing burden of cardiovascular diseases, thereby creating a favorable market environment for intravascular stents.

Growing adoption of minimally invasive procedures for the treatment of cardiovascular diseases is another major growth driver for the intravascular stents market. Minimally invasive techniques offer benefits such as shorter recovery times, reduced risk of complications, and improved patient outcomes, which are driving the demand for intravascular stents.

Industry

Report Scope

Report Coverage	Details
Segments Covered	Type, Mode Of Delivery, Product, End-Use
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Boston Scientific, Medtronic, Terumo Medical, Abbott, Biotronik, Lifetech, iVascular SLU, Stryker, Cook Medical, Microport Scientific, Stentys S.A., Hellman & Friedman, B Braun Melsungen AG

Stringent regulatory requirements for stent approval and reimbursement challenges are major restraints for the intravascular stents market. The lengthy and costly approval process for stents can act as a barrier for market growth, while insurers' reluctance to cover the high costs of stent procedures can limit patient access to these devices.

Increasing competition from alternative treatment options, such as drug therapy and surgical interventions, poses a challenge to the growth of the intravascular stents market. Patients and healthcare providers have a wide range of treatment options available for cardiovascular diseases, and the preference for non-invasive or less costly treatments could impact the demand for intravascular stents.